Abstract
The RT Cure project, supported from the Innovative Medicines Initiative (IMI) has been active for 6 years and involved several European and one Australian rheumatology institutions, six major pharma companies and a few small companies. The present report describes the major aims and results of the project which includenew understanding of specificity and regulation a of adaptive immunity that precedes RA and is active in established disease.use this understanding to predict risk for RA and establish registers of at risk for RA cohorts.support for clinical trials aimed at prevention of RA with knowledge and tools for immune surveillance.The progress in these areas, including the support to successful clinical trials for prevention will provide a basis for further development of prevention of RA using increasingly specific immunotherapies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
